Early initiation of Lu-177 PSMA radioligand therapy prolongs overall survival in metastatic prostate cancer

H Kulkarni, C Schuchardt, A Singh, T Langbein… - 2018 - Soc Nuclear Med
529 Objectives: The aim of this study was to determine the influence of timing of Lu-177
PSMA radioligand therapy (PRLT) in metastatic prostate cancer (mPC). Methods: Out of 512 …
Save Cite Cited by 13 Related articles All 2 versions

Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancer

CA Schneider, P Täger, J Hammes… - Nuklearmedizin …, 2022 - thieme-connect.com
Objective To examine the clinical benefit of Lu-177-PSMA-617 radioligand therapy for
patients with metastatic castration-resistant prostate cancer (mCRPC). Patients and Methods …
Save Cite Cited by 7 Related articles All 6 versions

Efficacy and safety of Ac-225 PSMA radio ligand therapy in metastatic prostate cancer. A systematic review and metanalysis

GK Parida, RA Panda, K Bishnoi, K Agrawal - Med Princ Pract, 2023 - karger.com
Abstract Background: Actinium-225 (Ac-225) labelled PSMA RLT has been tested recently in
metastatic castration-resistant prostate cancer (mCRPC), with encouraging results. Ac-225 …
Save Cite Cited by 4 Related articles All 4 versions
[HTML] springer.com

[HTML][HTML] Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up

PE Hartrampf, AK Seitz, FX Weinzierl… - European Journal of …, 2022 - Springer
Background Radioligand therapy (RLT) with 177Lu-labeled prostate-specific membrane
antigen (PSMA) ligands is associated with prolonged overall survival (OS) in patients with …
Save Cite Cited by 22 Related articles All 10 versions

Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer

A Yordanova, P Linden, S Hauser… - European journal of …, 2019 - Springer
Background Data are sparse regarding the feasibility of radioligand therapy (RLT) with [177
Lu] Lu-PSMA-617 as a retreatment. We aimed to assess the outcome and safety of …
Save Cite Cited by 66 Related articles All 7 versions

Predictive value of interim PSMA PET during 177Lu-PSMA radioligand therapy for overall survival in patients with advanced prostate cancer

A Gafita, W Weber, R Tauber, M Eiber - 2019 - Soc Nuclear Med
73 Introduction: 177 Lu-PSMA radioligand therapy (RLT) is a novel therapeutic agent that
has shown promising results in phase 2 trials in patients with metastatic castration-resistant …
Save Cite Cited by 6 Related articles All 2 versions
[PDF] snmjournals.orgFree from Publisher

Early experience of rechallenge 177Lu-PSMA radioligand therapy after an initial good response in patients with advanced prostate cancer

A Gafita, I Rauscher, M Retz, K Knorr… - Journal of Nuclear …, 2019 - Soc Nuclear Med
Our aim was to retrospectively evaluate the feasibility of rechallenge 177Lu-prostate-specific
membrane antigen (177Lu-PSMA) radioligand therapy. Methods: Rechallenge radioligand …
Save Cite Cited by 28 Related articles All 6 versions

177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer

A Bräuer, LS Grubert, W Roll, AJ Schrader… - European journal of …, 2017 - Springer
Purpose Radioligand therapies targeting prostate-specific membrane antigen (PSMA) have
been established for the treatment of metastasized castration-resistant prostate cancer …
Save Cite Cited by 182 Related articles All 6 versions
[PDF] snmjournals.orgFree from Publisher

Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617

J Ferdinandus, E Eppard, FC Gaertner… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Radioligand therapy (RLT) with 177Lu-PSMA-617 (PSMA is prostate-specific membrane
antigen) is a novel targeted therapy for metastatic prostate cancer. In this study, we …
Save Cite Cited by 119 Related articles All 6 versions
[HTML] springer.com

[HTML][HTML] Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks

S Rasul, M Hacker, E Kretschmer-Chott… - European journal of …, 2020 - Springer
Abstract Purpose [177 Lu] Lu-PSMA-617 radio-ligand therapy (PSMA-RLT) is emerging in
patients with an advanced metastatic castration-resistant prostate cancer (mCRPC). Here …
Save Cite Cited by 55 Related articles All 13 versions